Cardiff Oncology Announces New Lead Program In First-Line Metastatic Colorectal Cancer And Expanded Pfizer Relationship
Portfolio Pulse from Benzinga Newsdesk
Cardiff Oncology (NASDAQ:CRDF) has announced plans to advance its lead program to the first-line setting of metastatic colorectal cancer (mCRC) and conduct its new CRDF-004 trial with study execution support from Pfizer Ignite. The company's cash position on June 30, 2023, was $89.4 million, sufficient to fund operations into 2025 and through interim topline results from the mCRC trial. The company estimates that there are 48,000 new patients in the U.S. annually in the first-line RAS-mutated mCRC setting for whom there are no ongoing clinical trials and no new treatments approved in the past 20 years.
August 07, 2023 | 8:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cardiff Oncology's decision to advance its lead program to the first-line setting of mCRC and conduct its new CRDF-004 trial with Pfizer Ignite's support could potentially increase its market opportunity and patient impact. The company's strong cash position also indicates financial stability.
The advancement of Cardiff Oncology's lead program to the first-line setting of mCRC represents a significant step forward for the company, potentially increasing its market opportunity and patient impact. The company's strong cash position also indicates financial stability, which could attract investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer Ignite's support for Cardiff Oncology's new CRDF-004 trial in first-line RAS-mutated mCRC expands their relationship established in November 2021. This could potentially enhance Pfizer's reputation in the biotech industry.
Pfizer Ignite's support for Cardiff Oncology's new CRDF-004 trial in first-line RAS-mutated mCRC expands their relationship established in November 2021. This could potentially enhance Pfizer's reputation in the biotech industry and attract more partnerships.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80